First Oral Cancer Vaccine Using Bacterial Vector Shows Safety and Immune Response in Metastatic Urothelial Cancer Phase I Trial
A phase I study of B440 — the first oral cancer vaccine using a Bifidobacterium vector — shows a favorable safety profile and WT1-specific immune responses in metastatic urothelial cancer patients....
17 July, 2026